TW202110425A - 抗Aβ疫苗治療 - Google Patents
抗Aβ疫苗治療 Download PDFInfo
- Publication number
- TW202110425A TW202110425A TW109116790A TW109116790A TW202110425A TW 202110425 A TW202110425 A TW 202110425A TW 109116790 A TW109116790 A TW 109116790A TW 109116790 A TW109116790 A TW 109116790A TW 202110425 A TW202110425 A TW 202110425A
- Authority
- TW
- Taiwan
- Prior art keywords
- vaccine composition
- liposome vaccine
- disease
- amyloid
- liposome
- Prior art date
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0007—Nervous system antigens; Prions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6018—Lipids, e.g. in lipopeptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (8)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19175810.1 | 2019-05-21 | ||
| EP19175810 | 2019-05-21 | ||
| EP19185593.1 | 2019-07-10 | ||
| EP19185593 | 2019-07-10 | ||
| EP20171549 | 2020-04-27 | ||
| EP20171549.7 | 2020-04-27 | ||
| EP20172205 | 2020-04-29 | ||
| EP20172205.5 | 2020-04-29 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TW202110425A true TW202110425A (zh) | 2021-03-16 |
Family
ID=70740677
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW109116790A TW202110425A (zh) | 2019-05-21 | 2020-05-20 | 抗Aβ疫苗治療 |
Country Status (15)
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI916375B (zh) * | 2020-06-25 | 2026-03-01 | 英商梅迪繆思有限公司 | 軸突損傷之預防 |
| WO2024156912A1 (en) * | 2023-01-26 | 2024-08-02 | Ac Immune Sa | Anti-abeta vaccine therapy |
| WO2025109524A1 (en) * | 2023-11-22 | 2025-05-30 | Ac Immune Sa | Assays and methods for assessing vaccine preparations |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8663650B2 (en) | 2003-02-21 | 2014-03-04 | Ac Immune Sa | Methods and compositions comprising supramolecular constructs |
| CA2633399C (en) * | 2005-12-12 | 2016-01-26 | Ac Immune S.A. | Therapeutic vaccine |
| MX2011009654A (es) * | 2009-03-18 | 2011-10-12 | Ac Immune Sa | Metodo para uso terapeutico. |
| WO2012020124A1 (en) | 2010-08-12 | 2012-02-16 | Ac Immune S.A. | Vaccine engineering |
| EP2632434B1 (en) | 2010-10-26 | 2025-08-20 | AC Immune S.A. | Liposome-based construct comprising a peptide modified through hydrophobic moieties |
| CA2811188C (en) * | 2011-09-23 | 2020-04-28 | Andrea Pfeifer | Vaccine therapy |
| MA52180A (fr) * | 2018-04-10 | 2021-02-17 | Ac Immune Sa | Vaccins thérapeutiques anti-abêta |
-
2020
- 2020-05-20 CN CN202080035690.8A patent/CN113853214A/zh active Pending
- 2020-05-20 US US17/612,921 patent/US20220226447A1/en active Pending
- 2020-05-20 WO PCT/EP2020/064172 patent/WO2020234405A1/en not_active Ceased
- 2020-05-20 MY MYPI2021006840A patent/MY210394A/en unknown
- 2020-05-20 JP JP2021569155A patent/JP7701734B2/ja active Active
- 2020-05-20 SG SG11202112329RA patent/SG11202112329RA/en unknown
- 2020-05-20 IL IL288252A patent/IL288252B1/en unknown
- 2020-05-20 TW TW109116790A patent/TW202110425A/zh unknown
- 2020-05-20 AU AU2020277682A patent/AU2020277682A1/en active Pending
- 2020-05-20 KR KR1020217041697A patent/KR20220010552A/ko active Pending
- 2020-05-20 MX MX2021014102A patent/MX2021014102A/es unknown
- 2020-05-20 BR BR112021023209A patent/BR112021023209A2/pt unknown
- 2020-05-20 EP EP20726473.0A patent/EP3972633A1/en active Pending
- 2020-05-20 CA CA3138145A patent/CA3138145A1/en active Pending
-
2021
- 2021-11-18 CL CL2021003051A patent/CL2021003051A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL288252A (en) | 2022-01-01 |
| JP2022533422A (ja) | 2022-07-22 |
| MY210394A (en) | 2025-09-18 |
| KR20220010552A (ko) | 2022-01-25 |
| CN113853214A (zh) | 2021-12-28 |
| CA3138145A1 (en) | 2020-11-26 |
| SG11202112329RA (en) | 2021-12-30 |
| JP7701734B2 (ja) | 2025-07-02 |
| IL288252B1 (en) | 2026-06-01 |
| US20220226447A1 (en) | 2022-07-21 |
| WO2020234405A1 (en) | 2020-11-26 |
| BR112021023209A2 (pt) | 2022-01-18 |
| MX2021014102A (es) | 2022-02-11 |
| EP3972633A1 (en) | 2022-03-30 |
| CL2021003051A1 (es) | 2022-07-22 |
| AU2020277682A1 (en) | 2021-12-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Monsonego et al. | Increased T cell reactivity to amyloid β protein in older humans and patients with Alzheimer disease | |
| Zhang et al. | Curcuminoids enhance amyloid-β uptake by macrophages of Alzheimer's disease patients | |
| JP5889529B2 (ja) | アミロイド原性疾患の処置 | |
| CN106668852B (zh) | 一种治疗和/或预防ⅰ型糖尿病的组合物及其应用 | |
| US12324855B2 (en) | Method of safe administration of phosphorylated Tau peptide vaccine | |
| JP2022541582A (ja) | 自己免疫障害を処置するための組成物および方法 | |
| JP7701734B2 (ja) | 抗aベータワクチン療法 | |
| JP3420245B2 (ja) | ペプチドp277類似体及びこれを含む糖尿病の治療又は診断のための薬剤組成物 | |
| AU2021200093B2 (en) | Treatment and prevention of alzheimer's disease (ad) | |
| US20080248055A1 (en) | Immunomodulation by a therapeutic medication intended for treatment of diabetes and prevention of autoimmune diabetes | |
| CN109847058A (zh) | 疫苗疗法 | |
| Abicic et al. | New-onset ocular myasthenia gravis after booster dose of COVID-19 vaccine | |
| WO2015165980A2 (en) | Treatment and prevention of alzheimer's disease (ad) | |
| HK40058406A (en) | Anti-abeta vaccine therapy | |
| EA049756B1 (ru) | Терапия с помощью вакцины против бета-амилоида | |
| US20080226668A1 (en) | Immunomodulation by a therapeutic medication intended for treatment of diabetes and prevention of autoimmune diabetes | |
| US8871226B2 (en) | Methods and compositions for the treatment and diagnosis of cancer | |
| CN120583959A (zh) | 抗Aβ疫苗治疗 | |
| EP3269376A1 (en) | Treatment and prevention of alzheimer's disease (ad) | |
| CN118613496A (zh) | 安全施用Tau磷酸肽缀合物的方法 |